TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33637348
Drug: VB-111 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VB-111 and weekly paclitaxel 80 mg/m2
Study: 33637348
Drug: Post-treatment fever
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment fever
Study: 32726528
Drug: Nirsevimab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirsevimab (50 mg, single intramuscular injection)
Study: 34880671
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion during intraoperative period and 72 postoperative hours
Study: 34880671
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion at the same volume, infusion rate, and timing
Study: 34773928
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral relapse prevention therapy (RP)
Study: 36085294
Drug: CBD-rich cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD-rich cannabis treatment for 6 months
Study: 32249112
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of ready-to-use therapeutic foods (RUTF)
Study: 32249112
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of ready-to-use therapeutic foods (RUTF)
Study: 32249112
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (Standard and Reduced dose of RUTF)
Study: 32249112
Drug: Standard and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard and Reduced dose of RUTF
Study: 32555047
Drug: Ibuprofen (NSAID)
Normalized name: IBUPROFEN 200 mg ORAL TABLET [IBUPROFEN (NSAID) PAIN RELEIVER/ FEVER REDUCER]
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (NSAID)
Study: 36036648
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control (ERC) therapy
Study: 33742603
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg of decaffeinated green tea extract (dGTE) for 4 weeks
Study: 33068157
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (360 µg daily for 6 months)
Study: 33369020
Drug: PRT +
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PRT + ProD (whey protein 20 g each morning plus 20 g postexercise and vitamin D3 2000 IU/day)
Study: 36181108
Drug: Antibiotics combined
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics combined with mucosolvan perfusion therapy under fiber bronchoscope
Study: 36181108
Drug: Antibiotics combined
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics combined with mucosolvan lavage therapy under fiber bronchoscope
Study: 33263644
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg orally twice daily for 5 days)
Study: 33263644
Drug: Zanamivir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (10 mg inhaled twice daily for 5 days)
Study: 34076770
Drug: Inside-stent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inside-stent therapy
Study: 34076770
Drug: Conventional-stent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-stent therapy
Study: 34076770
Drug: Inside-stent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inside-stent therapy as second stent
Study: 36102002
Drug: Centrifugation (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrifugation (30 min daily)
Study: 35227041
Drug: G-premio Bond
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-premio Bond
Study: 34206160
Drug: iodine‐reduced kelp
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodine‐reduced kelp powder (6 g kelp powder corresponding to 3 g alginate/d)
Study: 32291210
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (phase 3)
Study: 32291210
Drug: 4-week treatment
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week treatment
Study: 32500827
Drug: Multi-strain probiotic
Normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strain probiotic supplementation (2 capsules daily for six months)
Study: 33530822
Drug: Relocation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relocation of intravenous pumps from bedside to outside the patient room using extension tubing
Study: 34752941
Drug: Two ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ketamine infusions (n=30; days 1 and 4)
Study: 34752941
Drug: Single ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ketamine infusion (n=24; only day 1)
Study: 34752941
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo infusion (n=24; only day 1)
Study: 34531554
Drug: Intrapolyp triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapolyp triamcinolone acetonide (TA) injection (20 mg/ml, 2 mL)
Study: 34531554
Drug: Placebo normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo normal saline injection (2 mL)
Study: 32488332
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg qd
Study: 32488332
Drug: Rabeprazole 5
Normalized name: RABEprazole 5 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 5 mg bid
Study: 32488332
Drug: Rabeprazole 5
Normalized name: RABEprazole 5 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 5 mg qd
Study: 34341409
Drug: Intrauterine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine antibiotic infusion (IAI) combined with oral antibiotic administration (OAA)
Study: 34341409
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic administration (OAA)
Study: 34341409
Drug: Intrauterine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine antibiotic infusion (IAI)
Study: 32702468
Drug: Chlorpropamide–glibenclamide–basal insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide–glibenclamide–basal insulin
Study: 35833450
Drug: Palliative Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative Medicine consultation within 24 hours
Study: 39269606
Drug: Ketamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusions
Study: 32781360
Drug: PBMC-therapy (intrauterine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMC-therapy (intrauterine administration of autologous hCG-activated PBMCs)
Study: 35349378
Drug: Hormone contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone contraceptives
Study: 34016410
Drug: Ranger drug‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranger drug‐coated balloon (DCB) (paclitaxel dose density 2 μg/mm2)
Study: 35943120
Drug: Ranger drug‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranger drug‐coated balloon (DCB)
Study: 32882390
Drug: Upstream administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upstream administration of ticagrelor before angiography
Study: 32882390
Drug: Downstream administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Downstream administration of ticagrelor or prasugrel after angiography
Study: 35091845
Drug: Pharmacist-led pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led pharmaceutical care program
Study: 33407845
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment plus oxygen (Control)
Study: 34344494
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (vitamin K antagonist and low molecular weight heparin)
Study: 34283841
Drug: Iron-containing micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-containing micronutrient powder (12.5 mg of iron daily)
Study: 34475094
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serum CEA, CKS2, OAS2, and ATG5
Study: 32469454
Drug: PCIT-ED (Parent-Child
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIT-ED (Parent-Child Interaction Therapy Emotion Development)
Study: 35510723
Drug: Tablet personal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet personal computer distraction (animated video played during IV placement)
Study: 35510723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no tablet distraction)
Study: 33675755
Drug: Monthly pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly pegcetacoplan (15 mg)
Study: 33675755
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other month (EOM) pegcetacoplan (15 mg)
Study: 35115017
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual in clinics
Study: 36048348
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of daily injectable vitamin B12
Study: 36048348
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of daily injectable vitamin B12 with other multinutrients (B12 + MV)
Study: 32493052
Drug: Intravenous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous continuous infusion (CI) of midazolam
Study: 32493052
Drug: Intravenous intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous intermittent bolus (IB) doses of midazolam
Study: 36197264
Drug: Medication combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication combined with schedule exercise therapy (MSET)
Study: 38654329
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST)
Study: 38061553
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (ST)
Study: 32272181
Drug: Thymoquinone (TQ)
Normalized name: Hydroquinone
DrugBank: Thymoquinone (DB16447)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thymoquinone (TQ) alone or in combination
Study: 33709982
Drug: Antihypertensive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapies
Study: 32951743
Drug: δ‐tocotrienol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: δ‐tocotrienol 300 mg twice daily
Study: 38734138
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment
Study: 33227785
Drug: Panic Control
Normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic Control Treatment (PCT)
Study: 33070253
Drug: Denosumab (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (specific antibody to human RANKL)
Study: 34662890
Drug: Apixaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (2.5 mg twice daily, later increased to 5 mg twice daily)
Study: 34662890
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target international normalized ratio 2-3)
Study: 34444833
Drug: Metformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (up to 2000 mg daily)
Study: 32611451
Drug: High intensity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity, high frequency peer reminders (monthly)
Study: 32611451
Drug: Monthly paper-based
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly paper-based reminders
Study: 32000828
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin for 6 months after index ERBD
Study: 35443676
Drug: DF-HA 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DF-HA 30 mg
Study: 33367782
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester (KME) drink containing 12 g β‐OHB
Study: 36219198
Drug: Furocyst® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furocyst® (2 capsules of 500 mg/day)
Study: 35440463
Drug: Fit-For-Fertility Programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fit-For-Fertility Programme (FFFP) for 6 months, then in combination with usual care for infertility if not pregnant; intervention duration up to 18 months or 24 months if pregnant.
Study: 34331930
Drug: Sublingual sufentanil
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual sufentanil cartridges (Zalviso)
Study: 34331930
Drug: Intravenous pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pain management (Control)
Study: 33870785
Drug: Home-based Pilates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based Pilates (twice-weekly, guided by a DVD)
Study: 33667420
Drug: R-MegaCHOEP (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-MegaCHOEP (high-dose chemotherapy plus rituximab followed by autologous HSCT)
Study: 33667420
Drug: R-CHOEP-14 (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOEP-14 (conventional chemotherapy plus rituximab)
Study: 33429762
Drug: Dexmedetomidine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.2 μg/kg/hour (group D1)
Study: 33429762
Drug: Dexmedetomidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4 μg/kg/hour (group D2)
Study: 33429762
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 0.2 μg/kg/hour (group C)
Study: 36303659
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (COC)
Study: 33469090
Drug: Silicon (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (2.5 mM) added to nutrient solution
Study: 33526397
Drug: Topical Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Vancomycin Powder and Dilute Povidone-Iodine (VIP) protocol
Study: 32240909
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (SCRT) followed by chemotherapy (6 cycles CAPOX or 9 cycles FOLFOX4)
Study: 32240909
Drug: Long-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course radiotherapy (25-28 × 2-1.8 Gy) with concomitant capecitabine followed by surgery and optional postoperative chemotherapy (8 cycles CAPOX or 12 cycles FOLFOX4)
Study: 36190481
Drug: 20,000 IU/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 IU/10 d (standard dose)
Study: 36190481
Drug: 60,000 IU/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU/10 d (high dose)
Study: 35214798
Drug: ShigETEC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ShigETEC vaccine (5 × 10^10 colony forming units)
Study: 35214798
Drug: ShigETEC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ShigETEC vaccine
Study: 33081606
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100 µg/25 µg
Study: 35584932
Drug: Prasugrel single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel single antiplatelet therapy (SAPT) after short-term dual antiplatelet therapy (DAPT)
Study: 36861447
Drug: Platinum-containing chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-containing chemotherapy
Study: 33526434
Drug: telephone cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: telephone cognitive-behavioural therapy (tCBT)
Study: 32040141
Drug: Outpatient integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outpatient integrated palliative care (PC) administered by a neurologist, social worker, chaplain, and nurse.
Study: 34151672
Drug: Drug Coated
Normalized name: Drug coated stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Coated Balloon (DCB) (Paclitaxel)
Study: 36102219
Drug: Maternal metabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal metabolic parameters (fasting glucose, insulin, HOMA-IR, leptin)
Study: 34676743
Drug: Conventional i-gel
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional i-gel insertion
Study: 32609011
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II therapy
Study: 34147116
Drug: Caffeinated chewing
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated chewing gum (5.4 mg/kg)
Study: 34147116
Drug: Caffeinated chewing
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated chewing gum (2.7 mg/kg)
Study: 35589595
Drug: Aspirin combined
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin combined with clopidogrel
Study: 33620407
Drug: Baclofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (50 to 150 mg per day)
Study: 32611648
Drug: Adavosertib (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (225 mg twice daily for 2.5 days/21-day cycle) plus carboplatin (AUC5) and paclitaxel (175 mg/m2)
Study: 32611648
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus carboplatin (AUC5) and paclitaxel (175 mg/m2)
Study: 33238961
Drug: propolis 100
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: propolis 100 µg/ml (P100)
Study: 33238961
Drug: propolis 250
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: propolis 250 µg/ml (P250)
Study: 33238961
Drug: chitosan-propolis nanoparticle
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: chitosan-propolis nanoparticle 100 µg/ml (CPN100)
Study: 33238961
Drug: chitosan-propolis nanoparticle
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: chitosan-propolis nanoparticle 250 µg/ml (CPN250)
Study: 35426733
Drug: Yoga program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program (75-min classes, twice weekly for 4 weeks, then once a week for 8 weeks, total 16 classes)
Study: 35426733
Drug: Educational film
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational film program (75-min classes, once weekly for 12 weeks, total 12 classes)
Study: 32565388
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Denosumab (120 mg every 3–4 weeks)
Study: 36180619
Drug: Perioperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative oral immunonutrition
Study: 34422262
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g sucrose in 500 ml water
Study: 34422262
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g sucrose in 500 ml water
Study: 34422262
Drug: 120 g
Normalized name: soap 120 gram TOPICAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g sucrose in 500 ml water
Study: 34863879
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora 5 mg/kg/day (Z5)
Study: 34863879
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora 10 mg/kg/day (Z10)
Study: 35675902
Drug: Sevoflurane anesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane anesthesia with morphine (10 mg/kg) (MACSEVO+MOR)
Study: 32100031
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics given to children
Study: 32100031
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use among children
Study: 32100031
Drug: Average number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Average number of antibiotic courses per child
Study: 32100031
Drug: Antibiotics given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics given without a prescription
Study: 32100031
Drug: Parental knowledge
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental knowledge of antibiotic indications
Study: 35383339
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day folate supplements
Study: 35435877
Drug: Mindfulness-based breathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based breathing and music therapy
Study: 32932009
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and care (Control group, n=30)
Study: 34247893
Drug: Laser-cane with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-cane with 15-min walking training and 15-min traditional physical therapy (EG)
Study: 35222899
Drug: Multidisciplinary combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary combined nondrug therapy